PONTE VEDRA, Fla. , Aug. 14, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc.
, (Nasdaq: CVKD ), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, will participate in the following upcoming conferences that will be available to investors by webcast. At the Sidoti and Investor Summit conferences, management will also participate in one-on-one institutional investor meetings. To request a meeting with management, please contact your conference representative or the Company's investor relations team at [email protected] .
Sidoti Micro-cap Virtual Conference Cadrenal Chief Medical Officer, Dr. Douglas Losordo , will present highlights of the Company's pipeline progress at the Sidoti Micro-cap Virtual Conference on Thursday, August 15, 2024 , at 2:30 p.m .
ET. The webcast can be accessed by visiting the investor relations section of the Company's website at https://www.cadrenal.
com/investors/ or accessed here . A replay of the presentation will also be available via these sites. Summer 2024 Investor Summit Cadrenal Chief Executive Officer, Quang Pham , will present an overview of the Company and its lead candidate tecarfarin at the Summer 2024 Investor Summit Virtual Conference on Tuesday, August 20, 2024 at 3 p.
m.